View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Protagonist Therapeutics Inc: 3 directors

A director at Protagonist Therapeutics Inc sold after exercising options 28,000 shares at 83.130USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...

Yun Zhong
  • Yun Zhong

PTGX's Own Programs Could Generate Excitement In 2026

Figure 1 - PN-8047 Has Comparable Potency with RusfertideSource: Company presentationFigure 2 - PN-458 Has Strong PotencySource: Company presentation

Yun Zhong
  • Yun Zhong

Rusfertide Ph3 And Ph2 Long-Term Data At ASH Show Strong Durability

Figure 1 - Rapid Response from Rusfertide TreatmentSource: Company data; Wedbush researchFigure 2 - Ph3 52-Week Data Show Durable Response from Rusfertide TreatmentSource: Company dataFigure 3 - Design of the REVIVE and THRIVE StudiesSource: Company data; Wedbush researchFigure 4 - Long-Term Rusfer

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Yun Zhong
  • Yun Zhong

INVITE: Wedbush Analyst Call On PTGX & JNJ Situation Overview

We do not find the reported M&A discussion between JNJ and PTGX to be surprising given the existing collaboration on icotrokinra, which after potential FDA and EMA approvals in 2026 for PsO and with ongoing Ph3 programs for both IBD and PsA should target an over $5B market based on JNJ manageme

Yun Zhong
  • Yun Zhong

Acquisition By JNJ Makes Sense But Valuation Is The Question

JNJ Only Needs to Pay at Most 10% Royalties on Icotrokinra to PTGX. Icotrokinra is included in a worldwide license and collaboration agreement that PTGX and JNJ initially entered into in May. '17 to co-develop and co-commercialize IL-23R antagonist compounds for various indications. A major milesto

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch